Literature DB >> 16929082

Infliximab use in patients with Crohn's disease: quality of life, costs and resource use.

C Koelewijn1, A Schrijvers, B Oldenburg.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16929082

Source DB:  PubMed          Journal:  Neth J Med        ISSN: 0300-2977            Impact factor:   1.422


× No keyword cloud information.
  6 in total

1.  Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease.

Authors:  Andrew P Yu; Scott Johnson; Si-Tien Wang; Pavel Atanasov; Jackson Tang; Eric Wu; Jingdong Chao; Parvez M Mulani
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 2.  Biosimilar Monoclonal Antibodies for Inflammatory Bowel Disease: Current Comfort and Future Prospects.

Authors:  Krisztina B Gecse; Péter L Lakatos
Journal:  Drugs       Date:  2016-10       Impact factor: 9.546

3.  Health care resource use and costs in Crohn's disease before and after infliximab therapy.

Authors:  Dustin E Loomes; Christopher Teshima; Philip Jacobs; Richard N Fedorak
Journal:  Can J Gastroenterol       Date:  2011-09       Impact factor: 3.522

Review 4.  Crohn's disease: a review of current treatment with a focus on biologics.

Authors:  Julián Panés; Fernando Gomollón; Carlos Taxonera; Joaquin Hinojosa; Juan Clofent; Pilar Nos
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  An exploratory analysis of healthcare costs and utilization of pediatric patients with Crohn's disease.

Authors:  Heidi C Waters; Rhadjena P Hilliard; Elton Teng; Mirza I Rahman; Ron Ferrer; Juvairiya Pulicharam; Bijan Nejadnik
Journal:  Dig Dis Sci       Date:  2009-12       Impact factor: 3.199

6.  Different therapeutic approaches on quality of life in patients with inflammatory bowel disease.

Authors:  Junjie Xu; Hui Lin; Xu Feng; Minyue Tang; Jun Shen; Zhihua Ran
Journal:  BMC Gastroenterol       Date:  2014-11-25       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.